July 5 (Reuters) - Beigene Ltd
* Beigene initiates pivotal trial of PD-1 antibody BGB-a317 in China in patients with urothelial cancer
* Beigene Ltd - plan to expand development program for BGB-A317 in China and other geographies, both as monotherapy and in combination
* Beigene - trial’s primary endpoint is ORR according to response evaluation criteria in solid tumors version 1.1 as assessed by independent review Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.